中国临床药理学杂志2026，Vol.42Issue(10)：1371-1377,7.DOI:10.13699/j.cnki.1001-6821.2026.10.004
儿童侵袭性克林霉素耐药社区相关性MRSA感染的诊疗与结局
Diagnosis,treatment,and outcomes of invasive clindamycin-resistant community-associated MRSA infections in children
摘要
Abstract
Objective This study aimed to reassess the antibiotic treatment regimen for invasive community-associated methicillin-resistant Staphylococcus aureus(CA-MRSA)infections at a tertiary children's hospital.Methods A retrospective analysis was conducted on cases of invasive clindamycin-resistant MRSA infections in children without underlying diseases between 2021 and 2025.A total of 34 children met the inclusion criteria,with the most common types of diagnosis being osteomyelitis(17 cases)and deep abscess(7 cases).Results The median duration of intravenous(Ⅳ)antibiotic therapy was 11.5 days(interquartile range[IQR],6-42 days),and the total treatment duration(Ⅳ+oral)was 32 days(IQR,23-42 days).Overall,50％of the children were subsequently switched to oral antibiotic therapy.The definitive antibiotics used for treatment included vancomycin(15 cases),TMP-SMX(trimethoprim-sulfamethoxazole,9 cases),linezolid(7 cases),ceftaroline(2 cases),and doxycycline(1 case).The cure rates of different definitive antibiotic treatment regimens were similar:73.3％in the vancomycin group,88.9％in the TMP-SMX group,50％in the ceftaroline group,and 100％in both the linezolid group and the doxycycline group.Three children died from MRS A infection,among whom 2 were treated with vancomycin and 1 with ceftaroline.Conclusion Vancomycin is the most commonly used drug for the treatment of invasive clindamycin-resistant CA-MRSA infections in children.However,in specific cases,TMP-SMX and linezolid may be considered as oral alternative options during the completion phase of treatment.Further research is still needed in the future to optimize the treatment regimen for such infections.关键词
耐甲氧西林金黄色葡萄球菌/侵袭性/克林霉素耐药/儿童Key words
MRSA/invasive/clindamycin-resistant/children分类
医药卫生引用本文复制引用
程明,张晓娟..儿童侵袭性克林霉素耐药社区相关性MRSA感染的诊疗与结局[J].中国临床药理学杂志,2026,42(10):1371-1377,7.基金项目
无锡市卫生健康委科研项目(M202407) （M202407）
